A Pennsylvania man has filed a Benicar lawsuit against the Japanese pharmaceutical giant, Daiichi Sankyo for allegedly causing him to suffer chronic diarrhea and potentially permanent intestinal damage as a direct result of using the hypertension medication Benicar.

Plaintiff David F. was suffering from high blood pressure and consequently faced a greater risk of a heart attack.

So to improve his chances of greater longevity, David was prescribed Benicar in 2011 that would have ideally have encouraged him to live a healthier and active lifestyle. Unfortunately, it was not long after he was prescribed the drug that David started suffering unexpected Benicar complications.

Among the injuries reported in his Benicar lawsuit include chronic diarrhea, nausea, vomiting, dehydration, weight loss, and other signs of nutrition deficiency. David’s medical record indicates that he may have suffered permanent damage in his gastrointestinal tract, which would be detrimental to his nutritional health and well-being.

It was not until the FDA released a public warning regarding Benicar side effects in July 2013, when David learned that his Benicar complications could have been avoided.

The FDA warning stated that a number of Benicar patients had suffered unexpected weight loss due to chronic diarrhea, vomiting, nausea, and permanent intestinal damage. The agency had issued this warning after receiving numerous Benicar injury reports, as well as study data from the Mayo Clinic in 2012.

Overview of Benicar Complications

Before the FDA warning, a number of doctors had misdiagnosed Benicar patients as suffering from Celiac disease due to the similarity in symptoms. This was soon debunked after the FDA announcement, as no other medication in Benicar’s class has been shown to cause such symptoms.

A number of critics blame the drug’s manufacturing company, Daiichi Sankyo, for failing to protect consumers and prioritizing Benicar’s advertising campaign. Upon its release, Daiichi Sankyo had aggressively advertised Benicar to clinics and physicians across the country, mainly through individual meetings and giving out clinical samples.

At no point during its marketing campaign, did Daiichi Sankyo mention the possibility of chronic diarrhea or intestinal damage, causing complications for thousands of patients including the plaintiff.

David states that at no point in time did Daiichi Sankyo notify him or his physician of these side effects, nor did the company provide any relevant studies. David insists that he never would have taken Benicar, if he had known about its possible complications.

David’s lawyer states that the pharmaceutical company had the civil responsibility of warning their client of all potential complications associated with Benicar, because they rely on the given information.

So for being allegedly responsible for manufacturing, selling, distributing, and marketing a dangerous drug, David is suing Daiichi Sankyo. The charges include: negligence, false advertising, concealing information, and misrepresenting a product.

The Benicar Lawsuit is filed as part of the consolidated Benicar Litigation known as In re: Benicar (Olmesartan) Products Liability Litigation, MDL No. 2606, in the U. S. District of New Jersey, Camden Vicinage.